Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA
No abstract is available for this item.
Volume (Year): 19 (2010)
Issue (Month): 10 ()
|Contact details of provider:|| Web page: http://www3.interscience.wiley.com/cgi-bin/jhome/5749|
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Gary Becker & Kevin Murphy & Tomas Philipson, 2007.
"The Value of Life Near its End and Terminal Care,"
NBER Working Papers
13333, National Bureau of Economic Research, Inc.
- Ernst Berndt & Iain Cockburn & Karen Grépin, 2006. "The Impact of Incremental Innovation in Biopharmaceuticals," PharmacoEconomics, Springer, vol. 24(2), pages 69-86, December.
- Frank R. Lichtenberg & Joel Waldfogel, 2003. "Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act," NBER Working Papers 9750, National Bureau of Economic Research, Inc.
- Nord, Erik, 1993. "The trade-off between severity of illness and treatment effect in cost-value analysis of health care," Health Policy, Elsevier, vol. 24(3), pages 227-238, August.
- Ubel, Peter A. & Loewenstein, George, 1996. "Distributing scarce livers: The moral reasoning of the general public," Social Science & Medicine, Elsevier, vol. 42(7), pages 1049-1055, April.
- Perry, Cynthia D., 2008. "Does treating maternal depression improve child health management The case of pediatric asthma," Journal of Health Economics, Elsevier, vol. 27(1), pages 157-173, January.
- Paul Dolan & Rebecca Shaw & Aki Tsuchiya & Alan Williams, 2005. "QALY maximisation and people's preferences: a methodological review of the literature," Health Economics, John Wiley & Sons, Ltd., vol. 14(2), pages 197-208.
- Nancy Devlin & David Parkin, 2004. "Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 437-452.
- Paul Dolan & Daniel Kahneman, 2008. "Interpretations Of Utility And Their Implications For The Valuation Of Health," Economic Journal, Royal Economic Society, vol. 118(525), pages 215-234, 01.
- Allan Wailoo & Aki Tsuchiya & Christopher McCabe, 2009. "Weighting Must Wait: Incorporating Equity Concerns into Cost-Effectiveness Analysis May Take Longer than Expected," PharmacoEconomics, Springer Healthcare | Adis, vol. 27(12), pages 983-989.
- Dolan, Paul & Edlin, Richard & Tsuchiya, Aki & Wailoo, Allan, 2007. "It ain't what you do, it's the way that you do it: Characteristics of procedural justice and their importance in social decision-making," Journal of Economic Behavior & Organization, Elsevier, vol. 64(1), pages 157-170, September.
- Nicholas A. Christakis & Paul D. Allison, 2009. "Inter-Spousal Mortality Effects: Caregiver Burden Across the Spectrum of Disabling Disease," NBER Chapters, in: Health at Older Ages: The Causes and Consequences of Declining Disability among the Elderly, pages 455-477 National Bureau of Economic Research, Inc.
- Yin, Wesley, 2008. "Market incentives and pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 27(4), pages 1060-1077, July.
- Anupam Jena & Tomas Philipson, 2009. "Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption," NBER Working Papers 15032, National Bureau of Economic Research, Inc.
When requesting a correction, please mention this item's handle: RePEc:wly:hlthec:v:19:y:2010:i:10:p:1109-1116. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Wiley-Blackwell Digital Licensing)or (Christopher F. Baum)
If references are entirely missing, you can add them using this form.